

Notice of References Cited	Application/Control No. 10/536,636		Applicant(s)/Patent Under Reexamination DURRANT, GILLIAN LINDY	
	Examiner Maher M. Haddad		Art Unit 1644	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-7,267,821	09-2007	Durrant et al.	424/130.1
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Golay et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 1 December 2001, Vol. 98, No. 12, pp. 3383-3389.
	V	Golay et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000 Jun 15;95(12):3900-8.
	W	Spendlove et al. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Volume 30 Issue 10, Pages 2944 - 2953, Nov. 2000.
	X	Durrant et al. Flow Cytometric Screening of Monoclonal Antibodies for Drug or Toxin Targeting to Human Cancer. Journal of the National Cancer Institute, 81(9): 688-696, 1989.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.